Phase I, Phase I
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with ABBV-181 as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with ABBV-181. The study will consist of 2 phases: dose escalation and dose expansion.
- Trial withAbbVie, Inc.
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Armand Russo, MD
- Daniel P. Petrylak, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Joseph Kim, MD
- Katelyn Scott
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- Lynn Mastrianni
- Mandy DeMerchant
- Michael Hurwitz, MD, PhD
- Michelle Laspino
- Pamela L. Kunz, MD
- Sara Anastasio, RN
- Stacey Stein, MD
- Teresa White
- Thejal Srikumar, MD, MPH
- Vanna Dest
- Virginia Syombathy
- Last Updated11/10/2024
- Study HIC#2000025007